{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:37:59Z","timestamp":1791999479302,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.urology.2023.10.022","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T07:29:55Z","timestamp":1699428595000},"page":"121-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The Discontinuation Rate With Collagenase Clostridium histolyticum for Peyronie\u2019s Disease in a High-volume Practice Is Unexpectedly High: Identifying Opportunities for Patient Care Improvement"],"prefix":"10.1016","volume":"183","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2250-1848","authenticated-orcid":false,"given":"Kelly","family":"Lehner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Reza","family":"Roshandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manaf","family":"Alom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevann","family":"Helo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ziegelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2023.10.022_bib1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0022-5347(01)65359-X","article-title":"The anatomy of the tunica albuginea in the normal penis and Peyronie's disease","volume":"157","author":"Brock","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.10.022_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/282503","article-title":"A population-based study of Peyronie's disease: prevalence and treatment patterns in the United States","volume":"2011","author":"Dibenedetti","year":"2011","journal-title":"Adv Urol"},{"key":"10.1016\/j.urology.2023.10.022_bib3","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1111\/j.1743-6109.2008.00883.x","article-title":"Impact of Peyronie's disease on sexual and psychosocial functioning: qualitative findings in patients and controls","volume":"5","author":"Rosen","year":"2008","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2023.10.022_bib4","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1743-6109.2008.00895.x","article-title":"The chronology of depression and distress in men with Peyronie's disease","volume":"5","author":"Nelson","year":"2008","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2023.10.022_bib5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.21037\/tau.2016.05.14","article-title":"Psychological aspects of Peyronie's disease","volume":"5","author":"Terrier","year":"2016","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urology.2023.10.022_bib6","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jsxm.2016.04.062","article-title":"Evidence-based management guidelines on Peyronie's disease","volume":"13","author":"Chung","year":"2016","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2023.10.022_bib7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.sxmr.2022.01.001","article-title":"Penile modeling in Peyronie's disease: a systematic review of the literature","volume":"10","author":"Krishnappa","year":"2022","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.urology.2023.10.022_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/aja.aja_81_19","article-title":"Modern treatment strategies for penile prosthetics in Peyronie's disease: a contemporary clinical review","volume":"22","author":"Ziegelmann","year":"2020","journal-title":"Asian J Androl"},{"key":"10.1016\/j.urology.2023.10.022_bib9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.10.022_bib10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1756287216637569","article-title":"Collagenase Clostridium histolyticum in the management of Peyronie's disease: a review of the evidence","volume":"8","author":"Traore","year":"2016","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.urology.2023.10.022_bib11","first-page":"107","article-title":"Role of collagenase Clostridium histolyticum in Peyronie's disease","volume":"9","author":"Peak","year":"2015","journal-title":"Biologics"},{"key":"10.1016\/j.urology.2023.10.022_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jsm.12731","article-title":"Clinical safety and effectiveness of collagenase Clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study","volume":"12","author":"Levine","year":"2015","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2023.10.022_bib13","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jsxm.2017.08.008","article-title":"Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie's disease","volume":"14","author":"Nguyen","year":"2017","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2023.10.022_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.urology.2020.07.048","article-title":"Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute phase Peyronie's disease: a multi-institutional analysis","volume":"145","author":"Nguyen","year":"2020","journal-title":"Urology"},{"issue":"4 Pt 1","key":"10.1016\/j.urology.2023.10.022_bib15","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.juro.2015.10.065","article-title":"Restoration of penile function and patient satisfaction with intralesional collagenase Clostridium histolyticum injection for Peyronie's disease","volume":"195","author":"Ziegelmann","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.10.022_bib16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1743-6109.2007.00651.x","article-title":"The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study","volume":"5","author":"Jordan","year":"2008","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2023.10.022_bib17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.urology.2018.06.003","article-title":"Plaque calcification: an important predictor of collagenase Clostridium histolyticum treatment outcomes for men with Peyronie's disease","volume":"119","author":"Wymer","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.urology.2023.10.022_bib18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.urology.2020.01.035","article-title":"The influence of indentation deformity on outcomes with intralesional collagenase Clostridium histolyticum monotherapy for Peyronie's disease","volume":"139","author":"Ziegelmann","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.urology.2023.10.022_bib19","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jsxm.2019.03.007","article-title":"Efficacy of combined collagenase Clostridium histolyticum and RestoreX Penile traction therapy in men with Peyronie's disease","volume":"16","author":"Alom","year":"2019","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2023.10.022_bib20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/JU.0000000000000245","article-title":"Outcomes of a novel penile traction device in men with Peyronie's disease: a randomized, single-blind, controlled trial","volume":"202","author":"Ziegelmann","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.10.022_bib21","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.sxmr.2019.05.001","article-title":"Discontinuation from collagenase Clostridium histolyticum therapy for Peyronie's disease: review and single-center cohort analysis","volume":"7","author":"Amighi","year":"2019","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.urology.2023.10.022_bib22","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jsxm.2021.03.075","article-title":"Continuing collagenase Clostridium histolyticum injections among initial nonresponders results in significant curvature improvements in the majority of Peyronie's disease men","volume":"18","author":"Alom","year":"2021","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2023.10.022_bib23","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.urology.2023.02.019","article-title":"Incremental treatment response by cycle with collagenase Clostridium histolyticum for Peyronie's disease: a pooled analysis of two phase 3 trials","volume":"175","author":"Ziegelmann","year":"2023","journal-title":"Urology"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429523009925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429523009925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:17:33Z","timestamp":1758770253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429523009925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":23,"alternative-id":["S0090429523009925"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2023.10.022","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Discontinuation Rate With Collagenase Clostridium histolyticum for Peyronie\u2019s Disease in a High-volume Practice Is Unexpectedly High: Identifying Opportunities for Patient Care Improvement","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2023.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}